West Pharmaceutical Services (WST) Total Non-Current Liabilities (2009 - 2026)

West Pharmaceutical Services has disclosed Total Non-Current Liabilities across 18 years of filings, most recently posting $996.3 million for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities rose 4.51% year-over-year to $996.3 million; the TTM figure through Jun 2026 stood at $996.3 million (up 4.51% YoY), while the FY2025 annual figure was $1.0 billion, up 13.34% from the prior year.
• Total Non-Current Liabilities came in at $996.3 million for Q2 2026 at West Pharmaceutical Services, down from $1.0 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.0 billion in Q1 2026 to a low of $812.1 million in Q3 2022.
• Average Total Non-Current Liabilities over 5 years is $906.8 million, with a median of $890.8 million recorded in 2023.
• Year-over-year, Total Non-Current Liabilities declined 11.0% in 2022 and gained 18.68% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $880.3 million in 2022, then rose by 1.1% to $890.0 million in 2023, then advanced by 1.0% to $898.9 million in 2024, then advanced by 13.34% to $1.0 billion in 2025, then declined by 2.21% to $996.3 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $996.3 million in Q2 2026, $1.0 billion in Q1 2026, and $1.0 billion in Q4 2025.